Study reveals stark global inequities in HPV vaccine coverage across 84 countries, finding that nations with the highest burden of cervical cancer often have the lowest vaccination rates. However, new WHO recommendations and an increase in vaccine supply may help narrow this gap and improve equitable access.
Inventiva secures up to $380m for MASH treatment lanifibranor – Pharmaceutical Technology
The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in
October 14, 2024